Plasmodium falciparum surf4.1 in clinical isolates: From genetic variation and variant diversity to in silico design immunopeptides for vaccine development
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0312091 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Nitchakarn Noranate und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of medicine, King's Mongkut Institute of Technology (KMITL), Ladkrabang, Bangkok, Thailand. Hauptthemen laut MEDLINE: Plasmodium falciparum, Protozoan Proteins, Malaria Vaccines, Genetic Variation. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Mongkut's Institute of Technology Ladkrabang.
Abstract (Originalsprache)
SURFINs protein family expressed on surface of both infected red blood cell and merozoite surface making them as interesting vaccine candidate for erythrocytic stage of malaria infection. In this study, we analyze genetic variation of Pfsurf 4 . 1 gene, copy number variation, and frequency of SURFIN 4.1 variants of P . falciparum in clinical isolates. In addition, secondary structure prediction and immunoinformatic were employed to identify immunogenic epitopes in humoral response as proposed vaccine candidates. Overall, our data demonstrate extensive polymorphism of SURFIN 4.1 in both genetic and protein level. The surf 4 . 1 gene showed extensive genetic variation with total of 447 polymorphic sites with maximum of three variants as well as singlet/triplet bases indels and mini/microsatellites in the coding sequence. The exon1 encoding extracellular region exhibited higher variation compared to exon2 which coding for intracellular domain. Interestingly, selective pressure was detected on both extracellular region (Var1 and Var2) as well as intracellular region (WRD2 and WRD3). Importantly, extensive full gene analysis suggests adenosine insertion at three key points nucleotide bases (nt 2409/2410, 3809/3810, and 4439/4440) of exon2 could lead to frameshift mutation resulted in four different SURFIN 4.1 variants (TMs, WD1, WD2 and WD3). The SURFIN 4.1 variant TMs was the most observed type with 67% frequency (51/76). Along with more than one copy number of surf 4 . 1 gene was observed with frequency of 13% (9/70). Despite substantial polymorphism, analysis of relatedness within P . falciparum population using full coding sequence was able to group SURFIN 4.1 protein into five distinct clades and reduced into four clades when using only exon1 coding sequence. Also, predicted secondary structure revealed conserved structure of five helix domains of extracellular region which similar among four SURFIN 4.1 variant types. In addition, in silico design eight immunopeptides derived from SURFIN 4.1 , four of which are highly conserved and four of dimorphic epitopes, as potential vaccine candidates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of medicine, King's Mongkut Institute of Technology (KMITL), Ladkrabang, Bangkok, Thailand.
- Department of Parasitology and Entomology, Faculty of Public Health, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Nitchakarn Noranate
Förderung
- King Mongkut's Institute of Technology Ladkrabang
Zitieren
APA
Noranate, N., Sripanomphong, J., Mphande-Nyasulu, F. A., & Chaorattanakawee, S. (2024). Plasmodium falciparum surf4.1 in clinical isolates: From genetic variation and variant diversity to in silico design immunopeptides for vaccine development. PLOS ONE. https://doi.org/10.1371/journal.pone.0312091
Vancouver
Noranate N, Sripanomphong J, Mphande-Nyasulu FA, Chaorattanakawee S. Plasmodium falciparum surf4.1 in clinical isolates: From genetic variation and variant diversity to in silico design immunopeptides for vaccine development. PLOS ONE. 2024. doi:10.1371/journal.pone.0312091
BibTeX
@article{Noranate2024,
author = {Noranate, Nitchakarn and Sripanomphong, Jariya and Mphande-Nyasulu, Fingani Annie and Chaorattanakawee, Suwanna},
title = {Plasmodium falciparum surf4.1 in clinical isolates: From genetic variation and variant diversity to in silico design immunopeptides for vaccine development},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0312091}
}
EUVIMED